Developer docs
API playgroundTry for free, no card

Search company profiles

Deargen

Full company profile

uuid0002l3v

Namestring
Deargen
Legal namestring
Deargen Inc.
Websiteurl
deargen.me
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Deargen Inc. is a South Korea-based, privately held AI-driven drug discovery company founded in 2016 and headquartered in Seoul, with an R&D center in Daejeon and a US representative office in Suwanee, Georgia. The company has built a proprietary deep-learning platform called Dr.UG, which integrates four functional modules: DearTRANS (genome data analysis and biomarker prediction), DearDTI (drug-target interaction analysis for target discovery), MolEQ (molecule selection and lead optimization), and a Lead Optimization component. The platform spans the drug discovery workflow from target identification through molecule design, with a stated emphasis on treating undruggable disease targets using AI-driven precision medicine.

Deargen serves two principal customer segments: pharmaceutical and biotech companies that access its AI platform for drug discovery and target identification, and medical research institutions and hospitals engaged in joint research and biomarker discovery. The company's revenue model is enterprise B2B, monetized through direct sales of platform access/collaborations with pharma and biotech firms, supplemented by co-development and joint research partnerships (e.g., Serengen for drug discovery acceleration, Samsung Medical Center for precision medicine research). Specific pricing, contract structures, and revenue figures are not publicly disclosed; total disclosed funding is approximately US$19.2 million across a 2018 government TIPS grant, a 2020 Series A of ~US$2.6M, and a 2022 Series B of ~US$17M. Go-to-market is primarily direct enterprise engagement complemented by industry conferences and strategic partnerships, with a US office established to support overseas market entry.

Short descriptiontext

Deargen is a South Korea-based AI-driven drug discovery company whose proprietary Dr.UG deep learning platform identifies disease targets and designs small molecule drugs for pharmaceutical, biotech, and medical research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, deep learning pharma, genome biomarker analysis, drug-target interaction, lead optimization platform
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Platform
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Dr. UG
Description

AI platform for developing new drugs based on DEARGEN's deep learning technology, specializing in genome data analysis, biomarker prediction, molecule selection and optimization.

deargen.me
+3 more records
Core offering1 text field

Deargen provides an AI-based genome analysis and drug discovery service built on its proprietary Dr.UG deep learning platform, integrating genome data analysis, biomarker prediction, molecule selection, and lead optimization. The company enables pharmaceutical and biotech customers to discover new disease targets and design small molecules for precision medicine, with an emphasis on treating undruggable diseases. Core offerings combine software platform capabilities with collaborative drug discovery research through joint agreements with pharmaceutical companies and medical centers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Deargen offers a unified AI platform called Dr.UG, which encompasses multiple integrated modules: DearTRANS (genome data analysis and biomarker prediction), DearDTI (target discovery), MolEQ (molecule selection), and Lead Optimization. The platform leverages deep learning technology to support the complete drug discovery pipeline from target identification through molecule optimization for precision medicine.

Product and service5 records
1Dr.UG
CategoryAI Drug Discovery Platform
Description

AI platform for developing new drugs, specialized in genome data analysis, biomarker prediction, molecule selection and optimization, enabling discovery of new disease targets and design of small molecules for precision medicine. Targeted at pharmaceutical, biotech, and clinical research customers.

2DearTRANS
CategoryGenomics and Biomarker Analytics
Description

AI-powered module for genome data analysis and biomarker prediction, used for interpreting genomic information and identifying biomarkers relevant to drug discovery and precision medicine.

3DearDTI
CategoryTarget Discovery
Description

AI-powered target discovery capability focused on drug-target interaction analysis to identify and validate biological targets for drug development.

4MolEQ
CategoryMolecule Design and Lead Optimization
Description

AI-powered molecule selection and lead optimization capability used for identifying candidate molecules and optimizing leads in the drug discovery pipeline.

5Lead Optimization
CategoryLead Optimization
Description

AI-powered lead optimization capability for refining and improving drug candidate molecules as part of the drug discovery workflow.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deargen and Serengen partnered to accelerate drug discovery using AI-powered platform technologies. This strategic collaboration focuses on combining双方的 expertise in AI-driven drug discovery to develop novel therapeutic candidates.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deargen signed a joint research agreement with Samsung Medical Center for collaborative research initiatives in AI-powered healthcare and drug discovery applications. The partnership aims to advance precision medicine through joint research projects.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven precision medicine company with end-to-end drug discovery capabilities from target identification through clinical design — comparable business model centered on pharma partnerships and co-development.

TypeDirect peer
Description

AI-driven drug discovery company with explicit focus on undruggable targets and end-to-end pipeline from target ID to clinical development — the most directly comparable competitor to Deargen's positioning and platform breadth.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with deep learning across target identification, hit generation, and lead optimization — competes directly with Dr.UG's end-to-end workflow offering.

TypeDirect peer
Description

Computational drug discovery platform offering physics-based and AI/ML tools for molecular design and lead optimization — directly overlaps with Deargen's MolEQ and lead optimization modules and serves similar pharma/biotech customers.

TypeDirect peer
Description

AI + physics-based drug discovery platform covering small molecule design and lead optimization — closely mirrors Deargen's molecule selection and lead optimization capabilities and targets similar pharma customers.

TypeRegional player
Description

Korean AI drug discovery company with end-to-end pipeline from target ID to lead optimization — most direct regional comparable, operating in the same Korean ecosystem and competing for the same Samsung Medical Center-tier hospital partnerships.

TypeEmerging player
Description

AI small molecule discovery platform focused on hit identification and lead optimization via deep learning — partial overlap with Deargen's MolEQ and lead optimization modules, though more focused on hit generation than target discovery.

TypeDirect peer
Description

AI-driven drug discovery combining target identification, molecular design, and clinical strategy — competes in similar pharma partnership business model and addresses comparable therapeutic areas including undruggable targets.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed AI drug discovery company leveraging DeepMind's foundation models for drug design — operates at vastly greater scale than Deargen but addresses the same pharma partnership market with deeper AI/ML capabilities.

TypeRegional player
Description

Korean AI drug discovery company offering platform-based molecular design services — regional comparable in the Korean ecosystem, competing for similar pharma partnerships though narrower in scope than Deargen's full Dr.UG platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deargen

AI Drug Discovery Platformdeargen.me

Deargen is a South Korea-based AI-driven drug discovery company whose proprietary Dr.UG deep learning platform identifies disease targets and designs small molecule drugs for pharmaceutical, biotech, and medical research customers.

What Deargen does

Deargen Inc. is a South Korea-based, privately held AI-driven drug discovery company founded in 2016 and headquartered in Seoul, with an R&D center in Daejeon and a US representative office in Suwanee, Georgia. The company has built a proprietary deep-learning platform called Dr.UG, which integrates four functional modules: DearTRANS (genome data analysis and biomarker prediction), DearDTI (drug-target interaction analysis for target discovery), MolEQ (molecule selection and lead optimization), and a Lead Optimization component. The platform spans the drug discovery workflow from target identification through molecule design, with a stated emphasis on treating undruggable disease targets using AI-driven precision medicine.

Deargen serves two principal customer segments: pharmaceutical and biotech companies that access its AI platform for drug discovery and target identification, and medical research institutions and hospitals engaged in joint research and biomarker discovery. The company's revenue model is enterprise B2B, monetized through direct sales of platform access/collaborations with pharma and biotech firms, supplemented by co-development and joint research partnerships (e.g., Serengen for drug discovery acceleration, Samsung Medical Center for precision medicine research). Specific pricing, contract structures, and revenue figures are not publicly disclosed; total disclosed funding is approximately US$19.2 million across a 2018 government TIPS grant, a 2020 Series A of ~US$2.6M, and a 2022 Series B of ~US$17M. Go-to-market is primarily direct enterprise engagement complemented by industry conferences and strategic partnerships, with a US office established to support overseas market entry.

Deargen firmographics

Firmographics
Name
Deargen
Legal name
Deargen Inc.
Website
https://deargen.me
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Deargen is a South Korea-based AI-driven drug discovery company whose proprietary Dr.UG deep learning platform identifies disease targets and designs small molecule drugs for pharmaceutical, biotech, and medical research customers.
Ownership category
akta.pro rank

Deargen industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Deep learning pharma
  • Genome biomarker analysis
  • Drug-target interaction
  • Lead optimization platform

Where Deargen is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Deargen business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Deargen product offering

Product offering

Core offering

Deargen provides an AI-based genome analysis and drug discovery service built on its proprietary Dr.UG deep learning platform, integrating genome data analysis, biomarker prediction, molecule selection, and lead optimization. The company enables pharmaceutical and biotech customers to discover new disease targets and design small molecules for precision medicine, with an emphasis on treating undruggable diseases. Core offerings combine software platform capabilities with collaborative drug discovery research through joint agreements with pharmaceutical companies and medical centers.

Product overview

Deargen offers a unified AI platform called Dr.UG, which encompasses multiple integrated modules: DearTRANS (genome data analysis and biomarker prediction), DearDTI (target discovery), MolEQ (molecule selection), and Lead Optimization. The platform leverages deep learning technology to support the complete drug discovery pipeline from target identification through molecule optimization for precision medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • Dr. UG: AI platform for developing new drugs based on DEARGEN's deep learning technology, specializing in genome data analysis, biomarker prediction, molecule selection and optimization.
  • DearTRANS
  • DearDTI
  • MolEQ

Products and services

  • Dr.UG AI platform for developing new drugs, specialized in genome data analysis, biomarker prediction, molecule selection and optimization, enabling discovery of new disease targets and design of small molecules for precision medicine. Targeted at pharmaceutical, biotech, and clinical research customers.
  • DearTRANS AI-powered module for genome data analysis and biomarker prediction, used for interpreting genomic information and identifying biomarkers relevant to drug discovery and precision medicine.
  • DearDTI AI-powered target discovery capability focused on drug-target interaction analysis to identify and validate biological targets for drug development.
  • MolEQ AI-powered molecule selection and lead optimization capability used for identifying candidate molecules and optimizing leads in the drug discovery pipeline.
  • Lead Optimization AI-powered lead optimization capability for refining and improving drug candidate molecules as part of the drug discovery workflow.

Companies that use Deargen

Customer profile

Segments2 records

Ideal customer profiles2 records

Deargen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Deargen partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SerengencoreStrategic or Co-development PartnerDeargen and Serengen partnered to accelerate drug discovery using AI-powered platform technologies. This strategic collaboration focuses on combining双方的 expertise in AI-driven drug discovery to develop novel therapeutic candidates.
  • Samsung Medical CentercoreStrategic or Co-development PartnerDeargen signed a joint research agreement with Samsung Medical Center for collaborative research initiatives in AI-powered healthcare and drug discovery applications. The partnership aims to advance precision medicine through joint research projects.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Deargen competitors and assessment

Company assessment

Direct peers

  • Exscientia: AI-driven precision medicine company with end-to-end drug discovery capabilities from target identification through clinical design — comparable business model centered on pharma partnerships and co-development.
  • Insilico Medicine: AI-driven drug discovery company with explicit focus on undruggable targets and end-to-end pipeline from target ID to clinical development — the most directly comparable competitor to Deargen's positioning and platform breadth.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with deep learning across target identification, hit generation, and lead optimization — competes directly with Dr.UG's end-to-end workflow offering.
  • Schrödinger: Computational drug discovery platform offering physics-based and AI/ML tools for molecular design and lead optimization — directly overlaps with Deargen's MolEQ and lead optimization modules and serves similar pharma/biotech customers.
  • XtalPi: AI + physics-based drug discovery platform covering small molecule design and lead optimization — closely mirrors Deargen's molecule selection and lead optimization capabilities and targets similar pharma customers.
  • BenevolentAI: AI-driven drug discovery combining target identification, molecular design, and clinical strategy — competes in similar pharma partnership business model and addresses comparable therapeutic areas including undruggable targets.

Regional players

  • Standigm: Korean AI drug discovery company with end-to-end pipeline from target ID to lead optimization — most direct regional comparable, operating in the same Korean ecosystem and competing for the same Samsung Medical Center-tier hospital partnerships.
  • PharmCADD: Korean AI drug discovery company offering platform-based molecular design services — regional comparable in the Korean ecosystem, competing for similar pharma partnerships though narrower in scope than Deargen's full Dr.UG platform.

Emerging players

  • Atomwise: AI small molecule discovery platform focused on hit identification and lead optimization via deep learning — partial overlap with Deargen's MolEQ and lead optimization modules, though more focused on hit generation than target discovery.

Broad incumbents

  • Isomorphic Labs: Alphabet-backed AI drug discovery company leveraging DeepMind's foundation models for drug design — operates at vastly greater scale than Deargen but addresses the same pharma partnership market with deeper AI/ML capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Deargen social profiles

Digital presence

Deargen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deargen leadership team

Management profile

Number of profiles

Profiles1 record

Deargen funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deargen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deargen

What does Deargen do?

Deargen provides an AI-based genome analysis and drug discovery service built on its proprietary Dr.UG deep learning platform, integrating genome data analysis, biomarker prediction, molecule selection, and lead optimization. The company enables pharmaceutical and biotech customers to discover new disease targets and design small molecules for precision medicine, with an emphasis on treating undruggable diseases. Core offerings combine software platform capabilities with collaborative drug discovery research through joint agreements with pharmaceutical companies and medical centers.

Is Deargen a public or private company?

Deargen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deargen founded?

Deargen was founded in 2016. It employs 1 to 10 people.

Where is Deargen based?

Deargen is headquartered in Daejeon, South Korea, in the Asia region.

Who are Deargen's main competitors?

Direct peers on record are Exscientia, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, XtalPi and BenevolentAI. Regional players are Standigm and PharmCADD. Atomwise is listed as an emerging player. Isomorphic Labs is listed as a broad incumbent.

Does Deargen have an API?

No public API is recorded for Deargen.

What industry is Deargen in?

Deargen's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooDeargen and Serengen Partner to Accelerate Drug DiscoverySerengen and Deargen announced a partnership to accelerate drug discovery by combining Serengen's DNA-encoded library technology with Deargen's AI-driven DearDTI platform. The collaboration aims to improve hit discovery diversity and accuracy, offering cost savings and faster lead generation. Both companies committed to ongoing collaboration.Business Wire BlogDeargen and Serengen Partner to Accelerate Drug DiscoverySerengen and Deargen announced a partnership to integrate Serengen's DNA-encoded library technology with Deargen's AI-driven DearDTI platform. The collaboration aims to accelerate hit identification, offering cost savings and faster lead generation. Both companies commit to ongoing collaboration to enhance drug discovery efficiency.PR NewswireDeargen Annonuces Patent Application for a TNBC Target Novel Drug Candidate Using AIDeargen, a South Korean AI-based drug discovery company, announced on December 22, 2021, that it has discovered and synthesized a new anticancer compound targeting triple-negative breast cancer (TNBC) using its proprietary AI platform and has filed a patent application for the first-in-class candidate. The company achieved this in just 10 weeks—2 weeks for target discovery and 8 weeks for substance design and synthesis—compared to the traditional 3-4 year drug development timeline. Deargen is establishing an R&D center called the iDear Center to further accelerate its pipeline development and expand its AI-driven NCE drug discovery capabilities.PR NewswireDeargen-FarmHannong, a Co-Development Agreement to Develop AI-Powered Crop Protection ProductsDeargen and FarmHannong signed a co-development agreement to use AI for discovering new crop protection product candidates. Deargen will use its AI platforms DearDTI and MolEQ, while FarmHannong will review candidates experimentally. The deal is the first AI crop protection collaboration in Korea, with FarmHannong paying upfront and milestone fees.